Page 1

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update Quarterly net revenues of $ 133.5 million , presenting 15 % growth versus the second quarter of 2020 with 79 % gross margin Invested record $ 50 million in research and development initiatives across brain , thoracic and abdominal programs St. Helier , Jersey - Novocure ( NASDAQ : NVCR ) today reported financial results for the quarter ended June 30 , 2021 , highlighting commercial strength and strategic investment across clinical , product development and commercial initiatives intended to fuel future growth . Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy , Tumor Treating Fields ( TTFields ) . TTFields are electric fields that disrupt cancer cell division . Second quarter 2021 highlights include : Financial , in millions Net revenues Gross Profit Net income ( loss ) Adjusted EBITDA ( 1 ) Non - financial Active patients at period end ( 2 ) Prescriptions received in period ( 3 ) Three Months Ended June 30 , 2021 2020 % Change 2021 Six Months Ended June 30 , 2020 % Change $ ŁA ŁA ŁA $ 133.5 $ 115.9 15 % $ $ 104.9 $ 90.5 16 % $ 268.2 $ 213.2 $ 217.8 23 % 167.8 27 % ( 14.6 ) $ 1.7 ( 959 ) % $ ( 18.8 ) $ 5.6 ( 436 ) % $ 18.1 $ 28.0 ( 36 ) % $ 39.2 $ 43.1 ( 9 ) % 3,487 1,450 3,278 6 % 3,487 3,278 6 % 1,422 2 % 2,852 2,831 1 % ( 1 ) Adjusted EBITDA is a non - U.S . GAAP measurement of earnings before interest , taxes , depreciation , amortization and share - based compensation . ( 2 ) An " active patient " is a patient who is receiving treatment under a commercial prescription order as of the measurement date , including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days . ( 3 ) A " prescription received " is a commercial order for Optune or Optune Lua that is received from a physician certified to treat patients for a patient not previously on Optune or Optune Lua . Orders to renew or extend treatment are not included in this total . " We delivered another quarter of strong performance , generating $ 134 million in net revenues with a 79 % gross margin , " said Asaf Danziger , Novocure's Chief Executive Officer . “ The performance of our core GBM business continues to provide our company